EUVIMEDEUVIMED entdecken
Open Access

Vaccine Treatment and Evaluation Units: Why Support a “Ready Base” of Clinical Trial Sites?

Emily J Erbelding, Jeanne M Marrazzo

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciaf376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Emily J Erbelding und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Ma…. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Vaccines, Vaccine Development. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The National Institute of Allergy and Infectious Diseases has funded a clinical trial infrastructure to advance products and strategies to improve treatment and prevention of infectious diseases. This infrastructure includes dedicated research clinics, such as the Vaccine and Treatment Evaluation Units (VTEUs). For more than 6 decades, the VTEUs have maintained quality systems to advance investigational products to licensure by conducting trials that de-risk private sector investment in clinical development. They have developed novel clinical trial approaches, such as controlled human challenge models, responded rapidly to pandemic threats, engaged impacted communities across a variety of diseases, and provided mentorship and training to the next generation of clinical investigators.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicVaccinesVaccine DevelopmentHumansUnited StatesNational Institute of Allergy and Infectious Diseases (U.S.)

Stichwörter der Autor:innen

clinical trialsinfrastructurepandemic responseresearch infrastructure

Substanzen

Vaccines

Autor:innen und Institutionen

  • Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
  • National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Förderung

  • NIAID NIH HHS

Zitieren

APA

Erbelding, E. J., & Marrazzo, J. M. (2025). Vaccine Treatment and Evaluation Units: Why Support a “Ready Base” of Clinical Trial Sites?. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf376

Vancouver

Erbelding EJ, Marrazzo JM. Vaccine Treatment and Evaluation Units: Why Support a “Ready Base” of Clinical Trial Sites?. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf376

BibTeX
@article{Erbelding2025,
  author = {Erbelding, Emily J and Marrazzo, Jeanne M},
  title = {Vaccine Treatment and Evaluation Units: Why Support a “Ready Base” of Clinical Trial Sites?},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciaf376}
}
Kostenlos starten →